Glaxo (GSK), Human Genome (HGSI) BENLYSTA Granted Marketing Authorization in Europe

GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) report the European Commission (EC) has granted marketing authorization for BENLYSTA (belimumab) 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sky Quarry names Heidi Bowman as CFO
• Magna Holdings makes unsolicited bid for 31% of Yatra Online
• Splash Beverage Group rebrands as Endovia Health Sciences on NYSE American